Andy Roddick defends Serena Williams' GLP-1 weight loss amid comeback talk

Former tennis star Andy Roddick has voiced support for Serena Williams' use of GLP-1 medication in her weight-loss efforts, suggesting it could aid a potential return to the court. Williams has shared how the treatment improved her health, while speculation grows following her inclusion in the anti-doping pool and practice sessions with younger players. Roddick emphasized the benefits for injury prevention during training.

In a recent episode of the Served podcast, Andy Roddick addressed criticism of Serena Williams' use of GLP-1 medication for weight loss. He stated that if he were attempting a comeback, he would prioritize rapid weight reduction to facilitate safer training. "I can tell you something that I think I know for a fact, right? I’m not Serena. I can’t play anymore. I stink. And if I decided that I wanted to come back, guess what I would be doing immediately? Immediately, I’d be dropping 20 pounds as fast as I can," Roddick said.

Roddick argued that starting lighter reduces injury risks during preparation, which is a major hurdle for returning athletes. "I would be taking those drugs because you know what becomes easier when you are 20 pounds lighter? Actually, getting back to the training that you need without getting injured to get back on tour," he explained. He added, "What it does is shortens the timeline for training and mitigates a lot of the risk in because the thing with getting back is like you get injured training, injured training, injured training, you can’t get back. Right."

Williams first discussed her use of the medication in an August 2025 interview with People Magazine and reinforced it in a Super Bowl XL advertisement in 2026. In a January 2026 interview with Today.com, she highlighted health improvements: "My blood sugar is better. I was able to lower my cholesterol by 30%. Some of these numbers [previous high cholesterol levels] are from when I was literally winning Grand Slams. It wasn’t, like, just playing tennis. I was dominating. I was at risk for heart disease, and I didn’t even know. … That’s scary."

Comeback rumors intensified after Williams' name appeared in the tennis anti-doping testing pool, a step often required for returning players. On the Today show in January 2026, she responded ambiguously: "I’m just having fun and enjoying my life right now," adding, "I don’t know, I’m just going to see what happens."

American player Alycia Parks recently practiced with Williams and commented on her fitness. "I actually practiced with her last Monday. And I messaged her yesterday. She’s definitely a good mentor to me, and she’s helped me a lot, especially in my practices," Parks told Tennis Majors. She added, "She is in great shape. So I think she would kill it on tour."

Support for Williams continues to build in the tennis community as discussions of a potential return, possibly emulating sister Venus, persist.

Articoli correlati

Serena Williams, fit and transformed, poses athletically with tennis racket against Super Bowl ad for Zepbound weight loss drug.
Immagine generata dall'IA

Serena Williams in spot Super Bowl per farmaco dimagrante

Riportato dall'IA Immagine generata dall'IA

Serena Williams apparirà in uno spot del Super Bowl che promuove la società di telemedicina Ro e il suo farmaco GLP-1 Zepbound per la perdita di peso. La leggenda del tennis di 44 anni discute della sua trasformazione corporea, avendo perso fino a 15,4 kg dall'inizio del trattamento. Lo spot arriva in mezzo a speculazioni continue su un possibile ritorno al tennis professionistico.

L'International Tennis Integrity Agency ha ufficialmente riammesso Serena Williams come giocatrice attiva, rimuovendola dall'elenco delle ritirate il 22 febbraio 2026. Questa mossa segue il suo rientro nel pool di test antidoping l'anno scorso, rendendola eleggibile per i tornei. Il suo ex coach Rick Macci ha espresso certezza su un ritorno, citando il suo allenamento intensivo.

Riportato dall'IA

Country star Jelly Roll has dropped nearly 300 pounds over two years without using popular GLP-1 medications like Ozempic. The 41-year-old singer opened up in Men's Health about tackling his food addiction through therapy instead. From low testosterone woes to reignited romance, he's spilling all the transformative tea.

Three Cochrane reviews commissioned by the World Health Organization evaluate GLP-1 receptor agonists like tirzepatide, semaglutide, and liraglutide for weight loss in people with obesity. The drugs show substantial weight reduction compared to placebo, but researchers note limitations in long-term data and industry funding influences. Side effects such as nausea are common, raising questions about broader access and safety.

Riportato dall'IA

L’eliminazione di Coco Gauff ai quarti dell’Australian Open 2026 è diventata controversa quando un video di lei che distrugge la sua racchetta è diventato virale. La leggenda del tennis Serena Williams ha offerto incoraggiamento, mentre diversi giocatori hanno sollevato preoccupazioni sulla privacy nelle aree dei giocatori. L’incidente ha evidenziato le pressioni emotive affrontate dagli atleti.

I top tennisti Carlos Alcaraz, Jannik Sinner e Aryna Sabalenka sono stati invitati a rimuovere i loro fitness tracker Whoop durante l'Australian Open 2026. I dispositivi, approvati per i circuiti ATP e WTA, restano vietati nei Grand Slam in mezzo a dibattiti sul benessere dei giocatori e sulle regole dati. Gli organizzatori del torneo sono in discussione per autorizzarli potenzialmente in futuro.

Riportato dall'IA

Retired tennis player Eugenie Bouchard has discussed the upheaval in her life following her 2014 Wimbledon final appearance, which brought sudden fame and high expectations. She described a rebellious phase that included a drastic hairstyle change, leading to the loss of a sponsorship deal. Now focused on pickleball, Bouchard emphasizes the complexity beyond her public image.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta